



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/180205/>

Version: Accepted Version

Article:

Iyizoba-Ebozue, Z, Murray, LJ, Ramasamy, S et al. (2021) Radiotherapy for Oropharyngeal Carcinoma With an Uninvolved Contralateral Neck: The Safety of Omission of Contralateral High Level II and Retropharyngeal Lymph Nodes From Elective Target Volumes. *Clinical Oncology*, 33 (5). pp. 331-339. ISSN: 0936-6555

<https://doi.org/10.1016/j.clon.2020.12.007>

© 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Highlights

- Radiotherapy for oropharynx cancer requires elective treatment of at risk lymph nodes.
- Limiting target volumes may reduce toxicity.
- Omission of contralateral high level II and retropharyngeal lymph nodes was safe.
- Omission could lead to lower contralateral parotid doses.